These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. Vierling JM; Zeuzem S; Poordad F; Bronowicki JP; Manns MP; Bacon BR; Esteban R; Flamm SL; Kwo PY; Pedicone LD; Deng W; Dutko FJ; DiNubile MJ; Koury KJ; Helmond FA; Wahl J; Bruno S J Hepatol; 2014 Aug; 61(2):200-9. PubMed ID: 24747798 [TBL] [Abstract][Full Text] [Related]
26. Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL. Lo Nigro L; La Spina M; Mirabile E; Pisana P; Schilirò G; Guardo P Pediatr Blood Cancer; 2004 Aug; 43(2):185. PubMed ID: 15236293 [No Abstract] [Full Text] [Related]
27. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817 [TBL] [Abstract][Full Text] [Related]
28. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P; Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225 [TBL] [Abstract][Full Text] [Related]
29. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. Kumada H; Toyota J; Okanoue T; Chayama K; Tsubouchi H; Hayashi N J Hepatol; 2012 Jan; 56(1):78-84. PubMed ID: 21827730 [TBL] [Abstract][Full Text] [Related]
30. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM; J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748 [TBL] [Abstract][Full Text] [Related]
31. Boceprevir: a protease inhibitor for the treatment of hepatitis C. Chang MH; Gordon LA; Fung HB Clin Ther; 2012 Oct; 34(10):2021-38. PubMed ID: 22975763 [TBL] [Abstract][Full Text] [Related]
32. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? Gluhovschi C; Gadalean F; Kaycsa A; Curescu M; Sporea I; Gluhovschi G; Petrica L; Velciov S; Bozdog G; Bob F; Vernic C; Cioca D Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):744-50. PubMed ID: 21320001 [TBL] [Abstract][Full Text] [Related]
33. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. Bräu N J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320 [TBL] [Abstract][Full Text] [Related]
35. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. Foote BS; Spooner LM; Belliveau PP Ann Pharmacother; 2011 Sep; 45(9):1085-93. PubMed ID: 21828346 [TBL] [Abstract][Full Text] [Related]
36. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV. Rivero-Juarez A; Lopez-Cortes LF; Girón-Gonzalez JA; Pineda JA; Rivero A; Lancet Infect Dis; 2014 Jan; 14(1):13-14. PubMed ID: 24355031 [No Abstract] [Full Text] [Related]
37. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients. Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511 [TBL] [Abstract][Full Text] [Related]
38. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. Manns MP; Markova AA; Calle Serrano B; Cornberg M Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J; J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185 [TBL] [Abstract][Full Text] [Related]
40. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V; J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]